Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Bi-Specific MAbS Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The bi-specific mabs market has experienced significant expansion in recent years. It is projected to grow from $11.64 billion in 2025 to $13.16 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.0%. The historical growth of this market can be attributed to factors such as the approval of initial bsabs therapies, an increasing incidence of hematological cancers, the early adoption of monoclonal antibodies, augmented investment in oncology research and development, and a rise in hospital-based clinical trials.
The bi-specific mabs market is expected to experience significant growth in the coming years, with its size projected to reach $21.83 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This expansion during the forecast period can be attributed to advancements in the integration of gene and cell therapies, the expanding pipeline of bsAbs, increased research and development funding for rare diseases, the growing adoption of precision medicine, and the emergence of novel bsAbs delivery platforms. Major trends anticipated in this period include the broadening applications of tumor immunotherapy, the development of multi-targeted bi-specific antibodies, a rise in treatments for hemophilia and other rare diseases, progress in both in vitro and in vivo platforms, and an increase in collaborations between pharmaceutical and biotechnology firms.
Get A Free Sample Report With In-Depth Market Insights:
Bi-Specific MAbS Market Growth Momentum: What Factors Are Shaping Demand?
The increasing incidence of cancer and other long-term illnesses is expected to drive the growth of the bispecific monoclonal antibodies market throughout the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. These antibodies are considered more effective than monoclonal antibodies (moAbs) as they target two or more tumor antigens on cells to disrupt cancer progression. For instance, in 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society (ACS), a US-based voluntary health organization, there will be an estimated 609,820 cancer-related deaths in the USA. Therefore, an increasing number of chronic diseases, including cancer, is anticipated to boost the demand for bi-specific MAbs to treat these diseases effectively.
Bi-Specific MAbS Market Breakdown By Product Type And Application
The bi-specific mabs market covered in this report is segmented –
1) By Drug: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Haemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-Users
Subsegments:
1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3
2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3
3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)
4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X
5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET
6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A
7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3
Bi-Specific MAbS Market Trends Redefining Industry Growth
Leading companies operating within the bi-specific mAbs market are concentrating on technological advancements, including CD20 x CD3 T-cell engaging bispecific antibodies, to address the increasing demand for more effective, off-the-shelf immunotherapies for hematological malignancies that offer specific treatment durations. A CD20 x CD3 bispecific antibody is engineered to facilitate close contact between T cells and B cells by simultaneously attaching to CD3 on T cells and CD20 on B cells, thus activating T-cell–mediated destruction of malignant B cells. Unlike traditional monoclonal antibodies that exclusively target B cells or T-cell checkpoints, this design leverages immune effector function in a highly directed manner. For instance, in June 2023, Roche AG, a biopharmaceutical company based in Switzerland, launched Columvi (glofitamab-gxbm), which is a CD20xCD3 bispecific T-cell engager. Columvi possesses a novel 2:1 structural format, incorporating two CD20-binding domains and one CD3-binding domain, and is administered as a fixed-duration therapy lasting approximately 8.5 months, aiming to provide durable responses for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Its fixed-duration regimen presents the possibility of a treatment-free interval following therapy, distinguishing it from continuous treatment strategies, and it has exhibited strong efficacy in clinical trials along with manageable safety.
Bi-Specific MAbS Market Company Landscape And Competitive Strategy
Major companies operating in the bi-specific mabs market are F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda Pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Sanofi S.A., Novo Nordisk A/S, Aspen Pharmacare, Baxter International
View The Full Bi-Specific MAbS Market Report:
Bi-Specific MAbS Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the bi-specific MAbs market in 2025. The regions covered in the bi-specific mabs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model